US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

OS Therapies

1.51

-0.0194-1.27%

Volume:28.94K

Turnover:44.41K

Market Cap:53.19M

PE:-1.94

High:1.55

Open:1.53

Low:1.51

Close:1.53

52wk High:2.57

52wk Low:1.12

Shares:35.21M

Float Shares:22.09M

Volume Ratio:0.73

T/O Rate:0.13%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7796

EPS(LYR):-0.8795

ROE:-914.04%

ROA:-225.11%

PB:14.63

PE(LYR):-1.72

Loading ...

Overview Company News Filings

BRIEF-OS Therapies U.S. FDA Granted A Waiver Of Application Fee

Os Therapies: Scheduled Type C Meeting With United States Food & Drug Administration on December 11, 2025 for Ost-Her2

THOMSON REUTERS

Os Therapies: Scheduled Pre-Marketing Authorisation Application Meeting With UK's Mhra on Dec 8 for Ost-Her2

THOMSON REUTERS

Os Therapies: U.S. FDA Granted a Waiver of Application Fee for Its Bla Filing for Ost-Her2

THOMSON REUTERS

OS Therapies Inc. reports 2-year overall survival rate of 75% for OST-HER2 in Phase 2b trial

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies Is Maintained at Buy by Lake Street

OS Therapies price target lowered to $17 from $18 at Lake Street

OS Therapies Reports Increased Losses Amid Rising R&D Costs

OS Therapies Is Maintained at Buy by D. Boral Capital

Os Therapies - US Biologics Licensing Application & UK Mhra Marketing Authorization Application Filings for Ost-Her2 Expected in January 2025

THOMSON REUTERS

OS Therapies Q3 EPS $(0.21) Misses $(0.13) Estimate

OS Therapies Reports Q3 2025 Results and Advances Regulatory Plans for OST-HER2

OS Therapies Reports Positive Survival Data from Phase 2b OST-HER2 Osteosarcoma Trial

OS Therapies Approves Key Proposals at Annual Meeting

OS Therapies Inc. held annual shareholder meeting

OS Therapies Releases Investor Presentation for Stakeholders

OS Therapies Inc. Unveils Cancer Immunotherapy Advances and Pipeline Highlights

Promising Regulatory Progress and Market Potential Justify Buy Rating for OS Therapies’ OST-HER2

OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate

Benzinga_recent_news

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OSTX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OSTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","market":"US","secType":"STK","nameCN":"OS Therapies","latestPrice":1.5106,"timestamp":1773842297775,"preClose":1.53,"halted":0,"volume":28940,"delay":0,"changeRate":-0.012679738562091558,"floatShares":22089100,"shares":35214352,"eps":-0.779604,"marketStatus":"Trading","change":-0.0194,"latestTime":"03-18 10:00:22 EDT","open":1.53,"high":1.5499,"low":1.5106,"amount":44413.841779999995,"amplitude":0.025686,"askPrice":1.56,"askSize":116,"bidPrice":1.47,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.779604,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773864000000},"marketStatusCode":2,"adr":0,"listingDate":1719460800000,"exchange":"AMEX","adjPreClose":1.53,"preHourTrading":{"tag":"盘前","latestPrice":1.52,"preClose":1.53,"latestTime":"09:14 EDT","volume":912,"amount":1386.6823200000001,"timestamp":1773839674040,"change":-0.01,"changeRate":-0.006536,"amplitude":0.03268},"postHourTrading":{"tag":"盘后","latestPrice":1.53,"preClose":1.53,"latestTime":"19:29 EDT","volume":13843,"amount":21202.601,"timestamp":1773790142977,"change":0,"changeRate":0,"amplitude":0.03268},"volumeRatio":0.729163},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","floatShares":22089100,"roa":"-225.11%","roe":"-914.04%","lyrEps":-0.879526,"volumeRatio":0.729163,"shares":35214352,"dividePrice":0,"high":1.5499,"amplitude":0.025686,"preClose":1.53,"low":1.5106,"week52Low":1.12,"pbRate":"14.63","week52High":2.57,"institutionHeld":0,"latestPrice":1.5106,"committee":-0.074074,"eps":-0.779604,"divideRate":0,"volume":28940,"delay":0,"ttmEps":-0.779604,"open":1.53,"prevYearClose":1.4,"prevWeekClose":1.55,"prevMonthClose":1.47,"prevQuarterClose":1.4,"fiveDayClose":1.55,"twentyDayClose":1.17,"sixtyDayClose":1.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OSTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OSTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OSTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OSTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OSTX","date":"2026-03-17","current":-1.93765,"percent":0.897561,"low":-14.897496,"twenty":-9.251798,"median":-4.801674,"eighty":-3.447432,"high":-2.23409,"avg":-5.990336,"sd":3.204183,"marketCap":52821528},"quantilePoints":[{"date":"2024-06-14","current":-13.217965,"twenty":-13.216533,"median":-13.214385,"eighty":-13.212238,"marketCap":102988885},{"date":"2024-06-21","current":-10.574372,"twenty":-13.217965,"median":-13.214385,"eighty":-12.156232,"marketCap":82391108},{"date":"2024-06-28","current":-13.217965,"twenty":-13.217965,"median":-13.217965,"eighty":-13.210806,"marketCap":102988885},{"date":"2024-08-02","current":-6.458845,"twenty":-13.217965,"median":-13.217965,"eighty":-11.101659,"marketCap":50324634},{"date":"2024-08-09","current":-8.117559,"twenty":-13.217965,"median":-10.433676,"eighty":-8.215548,"marketCap":63248641},{"date":"2024-08-16","current":-10.993719,"twenty":-13.216533,"median":-10.29298,"eighty":-8.15204,"marketCap":70975778},{"date":"2024-08-23","current":-13.004275,"twenty":-13.182439,"median":-10.833368,"eighty":-8.309008,"marketCap":83955991},{"date":"2024-08-30","current":-11.710317,"twenty":-13.188909,"median":-11.710317,"eighty":-8.610078,"marketCap":75602161},{"date":"2024-09-06","current":-12.939577,"twenty":-13.217965,"median":-12.391225,"eighty":-8.620371,"marketCap":83538300},{"date":"2024-09-13","current":-11.32213,"twenty":-13.217965,"median":-12.261039,"eighty":-9.289415,"marketCap":73096012},{"date":"2024-09-20","current":-11.483875,"twenty":-13.217965,"median":-11.710317,"eighty":-10.29298,"marketCap":74140241},{"date":"2024-09-27","current":-9.575287,"twenty":-13.210806,"median":-11.435351,"eighty":-9.575287,"marketCap":61818342},{"date":"2024-10-04","current":-9.727327,"twenty":-13.101322,"median":-11.354479,"eighty":-9.316172,"marketCap":62799917},{"date":"2024-10-11","current":-9.931126,"twenty":-13.068973,"median":-11.192735,"eighty":-9.413543,"marketCap":64115645},{"date":"2024-10-18","current":-9.769381,"twenty":-13.068973,"median":-10.859351,"eighty":-9.542938,"marketCap":63071416},{"date":"2024-10-25","current":-9.413543,"twenty":-13.004275,"median":-10.610453,"eighty":-9.542938,"marketCap":60774113},{"date":"2024-10-31","current":-8.782738,"twenty":-12.952517,"median":-10.592413,"eighty":-9.394069,"marketCap":56701621},{"date":"2024-11-08","current":-9.085848,"twenty":-12.836061,"median":-10.29298,"eighty":-9.218608,"marketCap":58658505},{"date":"2024-11-15","current":-7.116768,"twenty":-12.603148,"median":-10.141393,"eighty":-8.950952,"marketCap":45946065},{"date":"2024-11-22","current":-5.272053,"twenty":-12.423258,"median":-9.769381,"eighty":-8.605027,"marketCap":38782655},{"date":"2024-11-29","current":-6.178419,"twenty":-12.235002,"median":-9.759676,"eighty":-8.507772,"marketCap":45450128},{"date":"2024-12-06","current":-5.370028,"twenty":-11.917351,"median":-9.716005,"eighty":-8.143742,"marketCap":39503383},{"date":"2024-12-13","current":-12.876517,"twenty":-11.917351,"median":-9.704683,"eighty":-7.804035,"marketCap":94723165},{"date":"2024-12-20","current":-11.288606,"twenty":-11.937313,"median":-9.73218,"eighty":-8.125896,"marketCap":83042057},{"date":"2024-12-27","current":-14.738704,"twenty":-12.001827,"median":-9.761941,"eighty":-8.139646,"marketCap":108421919},{"date":"2025-01-03","current":-12.068126,"twenty":-12.384347,"median":-9.850254,"eighty":-8.168424,"marketCap":88776420},{"date":"2025-01-10","current":-14.782011,"twenty":-12.810182,"median":-10.086184,"eighty":-8.234384,"marketCap":108740495},{"date":"2025-01-17","current":-11.8949,"twenty":-12.876517,"median":-10.189917,"eighty":-8.475423,"marketCap":87502117},{"date":"2025-01-24","current":-8.430366,"twenty":-12.823449,"median":-10.125219,"eighty":-8.466412,"marketCap":62016063},{"date":"2025-01-31","current":-5.629868,"twenty":-12.632281,"median":-9.850254,"eighty":-8.128675,"marketCap":41414837},{"date":"2025-02-07","current":-5.600996,"twenty":-12.558673,"median":-9.759676,"eighty":-7.471942,"marketCap":41202453},{"date":"2025-02-14","current":-5.745352,"twenty":-12.423258,"median":-9.716005,"eighty":-6.985183,"marketCap":42264372},{"date":"2025-02-21","current":-5.456641,"twenty":-12.370592,"median":-9.688508,"eighty":-6.36129,"marketCap":40140534},{"date":"2025-02-28","current":-4.734863,"twenty":-12.322192,"median":-9.575287,"eighty":-6.039722,"marketCap":34830939},{"date":"2025-03-07","current":-4.850347,"twenty":-12.19815,"median":-9.413543,"eighty":-5.818713,"marketCap":35680475},{"date":"2025-03-14","current":-4.619378,"twenty":-12.093217,"median":-9.316172,"eighty":-5.658739,"marketCap":33981404},{"date":"2025-03-21","current":-4.590507,"twenty":-12.033481,"median":-9.267973,"eighty":-5.589448,"marketCap":33769021},{"date":"2025-03-28","current":-4.677121,"twenty":-11.941094,"median":-9.085848,"eighty":-5.445093,"marketCap":34406172},{"date":"2025-04-04","current":-3.682014,"twenty":-11.842932,"median":-9.000397,"eighty":-5.346931,"marketCap":32707102},{"date":"2025-04-11","current":-2.731469,"twenty":-11.788323,"median":-8.747948,"eighty":-5.012916,"marketCap":24263468},{"date":"2025-04-17","current":-3.828934,"twenty":-11.749136,"median":-8.669517,"eighty":-4.901959,"marketCap":34012183},{"date":"2025-04-25","current":-3.926486,"twenty":-11.61974,"median":-8.601309,"eighty":-4.833024,"marketCap":34878735},{"date":"2025-05-02","current":-4.706906,"twenty":-11.475058,"median":-8.516979,"eighty":-4.792605,"marketCap":41811155},{"date":"2025-05-09","current":-4.804459,"twenty":-11.45771,"median":-8.491597,"eighty":-4.792605,"marketCap":42677707},{"date":"2025-05-16","current":-4.048427,"twenty":-11.438586,"median":-8.234384,"eighty":-4.718089,"marketCap":35961926},{"date":"2025-05-23","current":-2.933033,"twenty":-11.406237,"median":-8.124506,"eighty":-4.677121,"marketCap":33145630},{"date":"2025-05-30","current":-3.928425,"twenty":-11.380358,"median":-7.63641,"eighty":-4.64825,"marketCap":44394361},{"date":"2025-06-06","current":-4.052742,"twenty":-11.348009,"median":-7.333748,"eighty":-4.596281,"marketCap":45799246},{"date":"2025-06-13","current":-4.574874,"twenty":-11.315425,"median":-7.167274,"eighty":-4.590507,"marketCap":51699762},{"date":"2025-06-20","current":-4.525147,"twenty":-11.288606,"median":-6.448552,"eighty":-4.525147,"marketCap":51137808},{"date":"2025-06-27","current":-4.500284,"twenty":-11.257432,"median":-6.245836,"eighty":-4.450557,"marketCap":50856831},{"date":"2025-07-03","current":-4.804944,"twenty":-11.153916,"median":-6.178419,"eighty":-4.480042,"marketCap":54299732},{"date":"2025-07-11","current":-4.384839,"twenty":-11.071717,"median":-6.001438,"eighty":-4.444649,"marketCap":49552214},{"date":"2025-07-18","current":-4.411096,"twenty":-11.057637,"median":-5.848373,"eighty":-4.413618,"marketCap":49848934},{"date":"2025-07-25","current":-5.118748,"twenty":-11.006503,"median":-5.726085,"eighty":-4.413618,"marketCap":57845975},{"date":"2025-08-01","current":-5.266689,"twenty":-10.886225,"median":-5.658739,"eighty":-4.423405,"marketCap":59517824},{"date":"2025-08-08","current":-5.177924,"twenty":-10.817778,"median":-5.632611,"eighty":-4.43502,"marketCap":58514715},{"date":"2025-08-15","current":-6.36145,"twenty":-10.649839,"median":-5.600996,"eighty":-4.43838,"marketCap":71889507},{"date":"2025-08-22","current":-5.360009,"twenty":-10.610453,"median":-5.567348,"eighty":-4.444649,"marketCap":76540639},{"date":"2025-08-29","current":-5.047341,"twenty":-10.610453,"median":-5.538676,"eighty":-4.449676,"marketCap":72075768},{"date":"2025-09-05","current":-4.667674,"twenty":-10.601601,"median":-5.456641,"eighty":-4.458388,"marketCap":66654139},{"date":"2025-09-12","current":-5.119065,"twenty":-10.582903,"median":-5.4212,"eighty":-4.477891,"marketCap":73099984},{"date":"2025-09-19","current":-4.897461,"twenty":-10.460155,"median":-5.370028,"eighty":-4.495136,"marketCap":69935483},{"date":"2025-09-26","current":-4.675856,"twenty":-10.329392,"median":-5.362697,"eighty":-4.515202,"marketCap":66770981},{"date":"2025-10-03","current":-4.409931,"twenty":-10.231142,"median":-5.325865,"eighty":-4.459866,"marketCap":62973579},{"date":"2025-10-10","current":-4.520733,"twenty":-10.170508,"median":-5.292169,"eighty":-4.471291,"marketCap":64555830},{"date":"2025-10-17","current":-4.099684,"twenty":-10.138159,"median":-5.266689,"eighty":-4.443146,"marketCap":58543277},{"date":"2025-10-24","current":-4.250282,"twenty":-10.078376,"median":-5.177924,"eighty":-4.421116,"marketCap":60693806},{"date":"2025-10-31","current":-4.156353,"twenty":-9.977535,"median":-5.177924,"eighty":-4.412988,"marketCap":59352507},{"date":"2025-11-07","current":-4.273765,"twenty":-9.834079,"median":-5.118748,"eighty":-4.402429,"marketCap":61029131},{"date":"2025-11-14","current":-4.273765,"twenty":-9.766275,"median":-5.104544,"eighty":-4.391176,"marketCap":61029131},{"date":"2025-11-21","current":-2.971008,"twenty":-9.761488,"median":-5.059977,"eighty":-4.38129,"marketCap":54322633},{"date":"2025-11-28","current":-3.447432,"twenty":-9.750618,"median":-5.0362,"eighty":-4.358965,"marketCap":63033690},{"date":"2025-12-05","current":-3.50521,"twenty":-9.73315,"median":-4.994703,"eighty":-4.321289,"marketCap":64090120},{"date":"2025-12-12","current":-3.909657,"twenty":-9.718269,"median":-4.969558,"eighty":-4.300776,"marketCap":71485134},{"date":"2025-12-19","current":-3.081503,"twenty":-9.704683,"median":-4.950787,"eighty":-4.273765,"marketCap":56342963},{"date":"2025-12-26","current":-2.927428,"twenty":-9.698213,"median":-4.936226,"eighty":-4.231496,"marketCap":53525815},{"date":"2026-01-02","current":-2.696315,"twenty":-9.672334,"median":-4.919621,"eighty":-4.226786,"marketCap":49300092},{"date":"2026-01-09","current":-2.965947,"twenty":-9.672334,"median":-4.910716,"eighty":-4.157441,"marketCap":54230102},{"date":"2026-01-16","current":-2.811872,"twenty":-9.575287,"median":-4.897871,"eighty":-4.145979,"marketCap":51412953},{"date":"2026-01-23","current":-2.831131,"twenty":-9.549408,"median":-4.897461,"eighty":-4.087363,"marketCap":51765097},{"date":"2026-01-30","current":-2.657797,"twenty":-9.439422,"median":-4.891008,"eighty":-3.973179,"marketCap":48595805},{"date":"2026-02-06","current":-2.445943,"twenty":-9.413543,"median":-4.875301,"eighty":-3.908145,"marketCap":44722227},{"date":"2026-02-13","current":-2.23409,"twenty":-9.413543,"median":-4.874269,"eighty":-3.823969,"marketCap":40848648},{"date":"2026-02-20","current":-2.311128,"twenty":-9.35512,"median":-4.850347,"eighty":-3.774842,"marketCap":42257222},{"date":"2026-02-27","current":-2.754094,"twenty":-9.300118,"median":-4.8312,"eighty":-3.691488,"marketCap":50356523},{"date":"2026-03-06","current":-2.908169,"twenty":-9.286254,"median":-4.804944,"eighty":-3.509217,"marketCap":53173671},{"date":"2026-03-13","current":-2.927428,"twenty":-9.264738,"median":-4.804459,"eighty":-3.458987,"marketCap":53525815},{"date":"2026-03-17","current":-2.888909,"twenty":-9.251798,"median":-4.801674,"eighty":-3.447432,"marketCap":52821528}],"updateTime":1773842422369},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OSTX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589979098","title":"BRIEF-OS Therapies U.S. FDA Granted A Waiver Of Application Fee","url":"https://stock-news.laohu8.com/highlight/detail?id=2589979098","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589979098?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:06","pubTimestamp":1764939961,"startTime":"0","endTime":"0","summary":"BRIEF-OS Therapies U.S. FDA Granted A Waiver Of Application Fee Dec 5  - OS Therapies Inc OSTX.A:OS THERAPIES: U.S. FDA GRANTED A WAIVER OF APPLICATION FEE FOR ITS BLA FILING FOR OST-HER2OS THERAPIES: SCHEDULED PRE-MARKETING AUTHORISATION APPLICATION MEETING WITH UK'S MHRA ON DEC 8 FOR OST-HER2OS THERAPIES: SCHEDULED TYPE C MEETING WITH UNITED STATES FOOD & DRUG ADMINISTRATION ON DECEMBER 11, 2025 FOR OST-HER2Source text: [ID:]Further company coverage: OSTX.A ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2589897970","title":"Os Therapies: Scheduled Type C Meeting With United States Food & Drug Administration on December 11, 2025 for Ost-Her2","url":"https://stock-news.laohu8.com/highlight/detail?id=2589897970","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589897970?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:03","pubTimestamp":1764939828,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2589897679","title":"Os Therapies: Scheduled Pre-Marketing Authorisation Application Meeting With UK's Mhra on Dec 8 for Ost-Her2","url":"https://stock-news.laohu8.com/highlight/detail?id=2589897679","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589897679?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:03","pubTimestamp":1764939828,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2589677897","title":"Os Therapies: U.S. FDA Granted a Waiver of Application Fee for Its Bla Filing for Ost-Her2","url":"https://stock-news.laohu8.com/highlight/detail?id=2589677897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589677897?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:03","pubTimestamp":1764939828,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2585836126","title":"OS Therapies Inc. reports 2-year overall survival rate of 75% for OST-HER2 in Phase 2b trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2585836126","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585836126?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:16","pubTimestamp":1763759777,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. reported a net loss of $6.9 million for the quarter, ending with approximately $1.9 million in cash. After the quarter, the company raised $7.8 million from warrant proceeds and has an at-the-market facility in place, extending its cash runway into late 2026. Key business developments included progress toward regulatory filings for OST-HER2, with a UK pre-MAA in December and an FDA Type C meeting on December 11, targeting filings in January 2026. The company also announced plans to spin off OS Animal Health in the first half of 2026, with current shareholders expected to receive direct equity in the new entity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDLGbkBS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OS Therapies Inc. reports 2-year overall survival rate of 75% for OST-HER2 in Phase 2b trial","news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2585367145","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2585367145","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585367145?lang=en_us&edition=fundamental","pubTime":"2025-11-21 21:22","pubTimestamp":1763731320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 21, 2025 08:22 ET (13:22 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2584577159","title":"OS Therapies Is Maintained at Buy by Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2584577159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584577159?lang=en_us&edition=fundamental","pubTime":"2025-11-19 02:19","pubTimestamp":1763489940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 13:19 ET (18:19 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2584955457","title":"OS Therapies price target lowered to $17 from $18 at Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2584955457","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584955457?lang=en_us&edition=fundamental","pubTime":"2025-11-18 22:39","pubTimestamp":1763476765,"startTime":"0","endTime":"0","summary":"Lake Street analyst Chad Messer lowered the firm’s price target on OS Therapies (OSTX) to $17 from $18 and keeps a Buy rating on the shares. The fi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/os-therapies-price-target-lowered-to-17-from-18-at-lake-street-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/os-therapies-price-target-lowered-to-17-from-18-at-lake-street-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX"],"gpt_icon":0},{"id":"2584360094","title":"OS Therapies Reports Increased Losses Amid Rising R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2584360094","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584360094?lang=en_us&edition=fundamental","pubTime":"2025-11-18 12:05","pubTimestamp":1763438720,"startTime":"0","endTime":"0","summary":"OS Therapies Incorporated ( ($OSTX) ) has released its Q3 earnings. Here is a breakdown of the information OS Therapies Incorporated presented to i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-reports-increased-losses-amid-rising-rd-costs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-reports-increased-losses-amid-rising-rd-costs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","OS","OSTX","BK4139"],"gpt_icon":0},{"id":"2584626506","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584626506","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584626506?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:24","pubTimestamp":1763385840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 08:24 ET (13:24 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2584899647","title":"Os Therapies - US Biologics Licensing Application & UK Mhra Marketing Authorization Application Filings for Ost-Her2 Expected in January 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584899647","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584899647?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:21","pubTimestamp":1763378480,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nFWN3WT16F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2584642692","title":"OS Therapies Q3 EPS $(0.21) Misses $(0.13) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2584642692","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584642692?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:04","pubTimestamp":1763377475,"startTime":"0","endTime":"0","summary":"OS Therapies Q3 EPS $(0.21) Misses $(0.13) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48893491/os-therapies-q3-eps-0-21-misses-0-13-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2584064251","title":"OS Therapies Reports Q3 2025 Results and Advances Regulatory Plans for OST-HER2","url":"https://stock-news.laohu8.com/highlight/detail?id=2584064251","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584064251?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:01","pubTimestamp":1763377288,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile  on November 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL3ddxGx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2577367291","title":"OS Therapies Reports Positive Survival Data from Phase 2b OST-HER2 Osteosarcoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2577367291","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577367291?lang=en_us&edition=fundamental","pubTime":"2025-10-22 21:16","pubTimestamp":1761138969,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. has announced additional overall and event free survival data from its 41-patient Phase 2b clinical trial of OST-HER2, an off-the-shelf immunotherapeutic candidate for recurrent, fully resected, pulmonary metastatic osteosarcoma. The company previously presented statistically significant positive final 2-year overall survival data from this trial on October 10, 2025. Subgroup analyses were performed following participation in an FDA/Osteosarcoma Institute workshop. The 1-year event free survival was reported as 28.6% among evaluable patients. OS Therapies plans to meet with regulatory agencies, including the FDA, MHRA, and EMA, to review the survival data and discuss plans to file for Biologics License Authorization under the FDA's Accelerated Approval Program and for conditional approvals in the UK and EU.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL472r3y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2577180775","title":"OS Therapies Approves Key Proposals at Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2577180775","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577180775?lang=en_us&edition=fundamental","pubTime":"2025-10-22 04:56","pubTimestamp":1761080163,"startTime":"0","endTime":"0","summary":"An announcement from OS Therapies Incorporated ( ($OSTX) ) is now available. On October 21, 2025, OS Therapies Incorporated held its annual meeting...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-approves-key-proposals-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-approves-key-proposals-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX","BK4097","OS","BK4139"],"gpt_icon":0},{"id":"2577680447","title":"OS Therapies Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2577680447","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577680447?lang=en_us&edition=fundamental","pubTime":"2025-10-22 04:16","pubTimestamp":1761077818,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. held its annual meeting of stockholders on October 21, 2025. Stockholders elected Paul A. Romness, John Ciccio, Avril McKean Dieser, Karim Galzahr, Olivier R. Jarry, and Theodore F. Search to the board of directors. Approval was granted for the issuance of shares of common stock to Ayala Pharmaceuticals, Inc. in connection with an asset purchase transaction. Stockholders also approved an amendment to increase the number of authorized shares of common stock from 50 million to 150 million. An amendment to the company's incentive compensation plan was approved, increasing the number of shares available for issuance under the plan and the maximum number of shares that may be granted to an individual as performance-based compensation. A resolution approving a shareholder rights agreement and authorizing the board of directors to implement it when deemed appropriate was adopted. Additionally, the appointment of MaloneBailey, LLP as independent registered public accounting f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL3vp3V2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADXS","OSTX","BK4139"],"gpt_icon":0},{"id":"2576062943","title":"OS Therapies Releases Investor Presentation for Stakeholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2576062943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576062943?lang=en_us&edition=fundamental","pubTime":"2025-10-18 05:28","pubTimestamp":1760736509,"startTime":"0","endTime":"0","summary":"OS Therapies Incorporated ( ($OSTX) ) just unveiled an announcement. On October 17, 2025, OS Therapies Incorporated announced the posting of an inv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-releases-investor-presentation-for-stakeholders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-releases-investor-presentation-for-stakeholders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4097","OS","OSTX"],"gpt_icon":0},{"id":"2576063323","title":"OS Therapies Inc. Unveils Cancer Immunotherapy Advances and Pipeline Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2576063323","media":"Reuters","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576063323?lang=en_us&edition=fundamental","pubTime":"2025-10-18 02:14","pubTimestamp":1760724872,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. has released a corporate presentation highlighting its recent developments and pipeline progress. The company has acquired all listeria-based assets from Advaxis/Ayala, with over $300 million invested in the listeria platform to date. Its lead clinical program, OST-HER2, targets osteosarcoma with additional applications in breast cancer and other solid tumors. The total addressable market for these assets and follow-on applications is estimated at $258 billion. OST-HER2 has received orphan drug, fast track, and rare pediatric disease designations from the FDA, and the company is preparing for meetings with global regulatory agencies regarding submissions for human osteosarcoma. Accelerated approval is targeted for 2026, and a Priority Review Voucher could be issued upon approval, with recent comparable sales valued at $160 million. Other pipeline highlights include a next-generation tunable drug conjugate  and ongoing clinical and preclinical programs in multiple canc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDLb9DPvd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADXS","BK4139","OSTX"],"gpt_icon":0},{"id":"2574102442","title":"Promising Regulatory Progress and Market Potential Justify Buy Rating for OS Therapies’ OST-HER2","url":"https://stock-news.laohu8.com/highlight/detail?id=2574102442","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574102442?lang=en_us&edition=fundamental","pubTime":"2025-10-11 03:45","pubTimestamp":1760125523,"startTime":"0","endTime":"0","summary":"Analyst Jason McCarthy of Maxim Group maintained a Buy rating on OS Therapies Incorporated, retaining the price target of $6.00. Jason McCarthy has...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-regulatory-progress-and-market-potential-justify-buy-rating-for-os-therapies-ost-her2-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-regulatory-progress-and-market-potential-justify-buy-rating-for-os-therapies-ost-her2-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX","PRGS","OST"],"gpt_icon":0},{"id":"2574170377","title":"OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2574170377","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574170377?lang=en_us&edition=fundamental","pubTime":"2025-10-10 22:40","pubTimestamp":1760107200,"startTime":"0","endTime":"0","summary":"OS Therapies reports 75% two-year survival in osteosarcoma trial, plans regulatory filings with the FDA, EMA, and MHRA following positive Phase 2b results.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/10/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/10/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/10/48149412/os-therapies-reports-strong-2-year-survival-data-for-bone-cancer-immunotherapy-candidate","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/10/48149412/os-therapies-reports-strong-2-year-survival-data-for-bone-cancer-immunotherapy-candidate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU2237443622.USD","LU0971096721.USD","OS","BK4006","LU2237443895.HKD","LU0267386448.USD","LU0882574139.USD","OSTX","BK4097","LU2237443382.USD","IE00BHPRN162.USD","BK4139","LU2237443978.SGD","LU2746668461.USD","IE00BZ1G4Q59.USD","IE00B1BXHZ80.USD","LU2746668974.SGD","LU0170899867.USD","LU2237443549.SGD","IE00BKVL7J92.USD","LU0149725797.USD","IE00BFXG1179.USD","LU1363072403.SGD","CMC","LU2237443465.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":52,"code":"91000000","status":"200"}]}}